Clin Osteol 2010; 15(3): 95-100

The parathyroid hormone circadian rhythm and its role in bone metabolismReview articles

M. Luchavová, V. Zikán

The circadian rhythm of parathyroid hormone (PTH) is well established in healthy subjects; however, its role in bone metabolism and factors controlling its physiology need to be clarified. The underlying rhythm of PTH is endogenous and external factors such as nu­ tritional, endocrine or neural factors can modulate its amplitude. In postmenopausal osteoporosis, the circadian rhythm of PTH is blunted and abnormalities in the PTH secretion pattern are observed. Restoration of endogenous PTH rhythm by modifying the hor­ monal environment or nutritional manipulation using timed calcium and phosphate loads may be important for stimulation of bone formation. Also calcilytics, which offer a novel approach to the treatment of osteoporosis, may require timed dosage respecting the en­ dogenous circadian rhythm of PTH for their optimal use.

Keywords: parathyroid hormone, circadian rhythm, osteoporosis, endocrinopathies, calcilytics

Published: December 11, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Luchavová M, Zikán V. The parathyroid hormone circadian rhythm and its role in bone metabolism. Osteologický bulletin. 2010;15(3):95-100.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Schmitt CP, Homme M, Schaefer F. Structural organization and biological r vance of oscillatory parathyroid hormone secretion. Pediatr Nephrol 2005;20: 346-351. Go to original source...
    2. Jubiz W, Canterbury JM, Reiss E, Tyler FH. Circadian rhythm in serum parat roid hormone concentration in human subjects: correlation with serum calcium, phosphate, albumin, and growth hormone levels. J Clin Invest 1972;51: 2040-2046. Go to original source...
    3. el-Hajj Fuleihan G, Klerman EB, Brown EN, Choe Y, Brown EM, Czeisler CA The parathyroid hormone circadian rhythm is truly endogenous - a general c cal research center study. J Clin Endocrinol Metab 1997;82:281-286. Go to original source...
    4. Joseph F, Chan BY, Durham BH, Ahmad AM, Vinjamuri S, Gallagher JA, Vora JP, Fraser WD. The circadian rhythm of osteoprotegerin and its associatio parathyroid hormone secretion. J Clin Endocrinol Metab 2007;92:3230-3238. Go to original source...
    5. Blumsohn A, Herrington K, Hannon RA, Shao P, Eyre DR, Eastell R. The effect of calcium supplementation on the Endocrinol Metab 1994;79:730-735. Go to original source...
    6. Calvo MS, Kumar R, Heath H. Persistently elevated parathyroid hormone secreti­ on and action in young women after four weeks of ingesting high phosphorus calcium diets. J Clin Endocrinol Metab 1990;70:1334-1340. Go to original source...
    7. Fraser WD, Logue FC, Christie JP, Cameron DA, O'Reilly DS, Beastall GH. Alteration of the circadian rhythm of intact parathyroid hormone following a hour fast. Clin Endocrinol 1994; 40:523-528. Go to original source...
    8. Joseph F, Ahmad AM, Ul-Haq M, Durham BH, Whittingham P, Fraser WD, Vora JP. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. J Bone Miner Res 2008;23:721-729. Go to original source...
    9. Logue FC, Fraser WD, O'Reilly DS, Christie J, Cameron DA, Wallace DC, Beastall GH. Sleep shift dissociates the nocturnal peaks of parathyroid horm (1-84), nephrogenous cyclic adenosine monophosphate, and prolactin in normal men. J Clin Endocrinol Metab 1992;75:25-29. Go to original source...
    10. Schmitt CP, Locken S, Mehls O, Veldhuis JD, Lehnert T, Ritz E, Schaefer F. PTH pulsatility but not calcium sensitivity is restored after total parathy with heterotopic autotransplantation. J Am Soc Nephrol 2003;14:407-414. Go to original source...
    11. Eastell R, Calvo MS, Burritt MF, Offord KP, Russell RG, Riggs BL. Abnormalities in circadian patterns of bone resorption and renal calcium co vation in type I osteoporosis. J Clin Endocrinol Metab 1992;74:487-494. Go to original source...
    12. Fraser WD, Logue FC, Christie JP, Gallacher SJ, Cameron D, O'Reilly DS, Beastall GH, Boyle IT. Alteration of the circadian rhythm of intact parathy hormone and serum phosphate in women with established postmenopausal osteo­ porosis. Osteoporos Int 1998;8:121-126. Go to original source...
    13. Fraser WD, Ahmad AM, Vora JP. The physiology of the circadian rhythm of pa­ rathyroid hormone and its potentia Nephrol Hypertens 2004;13:437 444. Go to original source...
    14. Jilka RL. Molecular and cellular mechanism of the anabolic effect of intermitt PTH. Bone 2007;40:1434-1446. Go to original source...
    15. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE. Catabolic effects of continuous human PTH (1-38) in vivo is sustained stimulation ofRANKL and inhibition of osteoprotegerin and gene-as­ sociated bone formation. Endocrinology 2001;142:4047-4054. Go to original source...
    16. Schlemmer A, Hassager C. Acute fasting diminishes the circadian rhythm of bio­ chemical markers of bone resorption. Eur J Endocrinol 1999; 140:332-337. Go to original source...
    17. Silverberg SJ, Shane E, de la Cruz L, Segre GV, Clemens TL, Bilezikian JP. Abnormalities in parathyroid hormone secretion and 1,25-dihydroxyvitamin D3 formation in women with osteoporosis. N Engl J Med 1989;320:277-281. Go to original source...
    18. Silverberg SJ, Bilezikian JP. Parathyroid function and responsiveness in osteo rosis. In: The parathyroids. Basic and clinical concepts. Second edition. Academic press, 2001:843-851. Go to original source...
    19. Logue FC, Fraser WD, Gallacher SJ, Cameron DA, O'Reilly DS, Beastall GH, Patel U, Boyle IT. The loss of circadian rhythm for intact parathyroid hormone and nephrogenous cyclic AMP in patients with primary hyperparathyroidism. Clin Endocrinol 1990;32:475^83. Go to original source...
    20. Gallagher SJ, Fraser WD, Logue FC. The lose of diurnal rhythm of PTH secreti­ on in untreated pseudohypoparathyroidism. Bone 1991;12:297. Go to original source...
    21. Santamaria R, Almaden Y, Felsenfeld A, Martin-Malo A, Gao P, Cantor T, Aljama P, Rodriguez M. Dynamics of PTH secretion in hemodialysis patients as determined by the intact and whole PTH assays. Kidney Int 2003;64:1867-1873. Go to original source...
    22. Ledger GA, Burritt MF, Kao PC, O'Fallon WM, Riggs BL, Khosla S. Role of pa­ rathyroid hormone in mediating nocturnal and age-related increases in bone re­ sorption. J Clin Endocrinol Metab 1995;80:3304-3310. Go to original source...
    23. Ledger GA, Burritt MF, Kao PC, O'Fallon WM, Riggs BL, Khosla S. Abnormalities of parathyroid hormone secretion in elderly women that are rever­ sible by short term therapy with 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1994;79:211-216. Go to original source...
    24. Vincent A, Riggs BL, Atkinson EJ, Oberg AL, Khosla S. Effect of estrogen re­ placement therapy on parathyroid hormone secretion in elderly postmenopausal women. Menopause 2003;10:165-171. Go to original source...
    25. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone neral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-2274. Go to original source...
    26. Kennel KA, Riggs BL, Achenbach SJ, Oberg AL, Khosla S. Role of parathyroid hormone in mediating Int 2003;14:631-636. Go to original source...
    27. Calvo MS, Eastell R, Offord KP, Bergstralh EJ, Burritt MF. Circadian variation ionized calcium and intact parathyroid hormone: evidence for sex differences in calcium homeostasis. J Clin Endocrinol Metab 1991;72:69-76. Go to original source...
    28. Harms HM, Schlinke E, Neubauer O, Kayser C, Wustermann PR, Horn R, Kulpmann WR, von zur Muhlen A, Hesch RD. Pulse amplitude and frequency modulation of parathormone in primary hyperparathyroidism. J Clin Endocrinol Metab 1994;78:53-57. Go to original source...
    29. Hock JM, Fonseca J. Anabolic effect of human synthetic parathyroid hormone (1-34) depends on growth hormone. Endocrinology 1990;127:1804-1810. Go to original source...
    30. Bikle DD. Growth hormone/insulin-like growth factor-1/PTH axis in bone. J Bone Miner Res 2008;23:581-583. Go to original source...
    31. Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 1993;76:1452-1457. Go to original source...
    32. Mazziotti G, Cimino V, De Menis E, Bonadonna S, Bugari G, De Marinis L, Veldhuis JD, Giustina A Active acromegaly enhances spontaneous parathyroid hormone pulsatility. Metabolism 2006;55:736-740. Go to original source...
    33. White HD, Ahmad AM, Durham BH, Chandran S, Ptwala A, Fraser WD, Vora JP. Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity. J Clin Endocrinol Metab 2006;91:913-919. Go to original source...
    34. White HD, Ahmad AM, Durham BH, Ptwala A, Whittingham P, Fraser WD, Vora JP. Growth hormone replacement is important for the restoration of parathy­ roid hormone sensitivity and improvement in bone metabolism in older adult growth hormone-deficient patients. J Clin Endocrinol Metab 2005;90:3371-3380. Go to original source...
    35. Bonadonna S, Burattin A, Nuzzo M, Bugari G, Rosei EA, Valle D, Iori N, Bilezikian JP, Veldhuis JD, Giustina A Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 2005;152:199-205. Go to original source...
    36. Oxlund H, Ortoft G, Thomsen JS, Danielsen CC, Ejersted C, Andreassen TT. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid tre­ atment. Bone 2006;39:244-252. Go to original source...
    37. Mauras N. Can growth hormone counteract the catabolic effects of steroids? Res 2009;72:48-54. Go to original source...
    38. Ahmad AM, Hopkins MT, Fraser WD, Ooi CG, Durham BH, Vora JP. Prathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency. Bone 2003;32:170-179. Go to original source...
    39. Galitzer H, Ben-Dov I, Lavi-Moshayoff V, Naveh-Many T, Silver J. Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secre on. Curr Opin Nephrol Hypertens 2008;17:363-367. Go to original source...
    40. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone for­ mation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009;150:4835^845. Go to original source...
    41. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaid ling. Cell 2003;115:151-162. Go to original source...
    42. Castro JH, Genuth SM, Klein L. Comparative response to para hyperthyroidism and hypothyroidism. Metabolism 1975;24:839-848. Go to original source...
    43. Magliola L, Forte LR. Prolactin stimulation of parath bovine parathyroid cells. Am J Physiol 1984;247:E675-680. Go to original source...
    44. Schmitt CP, Obry J, Feneberg R, Veldhuis JD, Mehls O, Ritz E, Schaefer F. B 1-adrenergic blockade augments pulsatile PTH secretion in humans. J Am Soc Nephrol 2003;14:325-350. Go to original source...
    45. Fu L, Patel MS, Bradley A, Wagn FF, Kasenty G. The molecular clock mediates leptin- regulated bone formation. Cell 2002;122:803-815. Go to original source...
    46. Harms HM, Neubauer O, Kayser C, Wustermann PR, Horn R, Brosa U, Schlinke E, Kulpmann WR, von zur Muhlen A, Hesch RD. Pulse amplitude and frequency modulation of parathyroid hormone in early postmenopausal women before and on hormone replacement therapy. J Clin Endocrinol Metab 1994;78:48-52. Go to original source...
    47. Raymond JP, Isaac R, Merceron RE, Wahbe F. Comparison between the plasma concentrations ofprolactin and parathyroid hormone in normal subjects and in pa­ tients with hyperpa 1982; 55:1222-1225.
    48. Davey RA, Turner AG, McManus JF, Chiu WS, Tjahyono F, Moore AJ, Atkin Anderson PH, Ma C, Glatt V, MacLean HE, Vincent C, Bouxsein M, Morris HA, Findlay DM, Zajac JD. Calcitonin receptor plays a physiological ro against hypercalcemia in mice. J Bone Miner Res 2008;23:1182-1193. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.